In the pending merger between Cambridge Antibody Technology and Oxford GlycoSciences, which the two companies announced on Jan. 23, a lot of questions remain as to what the combined company will look like, or what its new name will be. But there are indications that proteomics might play a smaller role in the new company than it has at OGS.

The merged firm is to be dominated by CAT’s management team and shareholders, with approximately $419 million in cash, two approved drugs, and 14 therapeutic products in either clinical or pre-clinical development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.